Navigation Links
VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
Date:7/7/2009

BEDFORD, Mass., July 7 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat-K FAST(TM) imaging agent for measuring and monitoring Cathepsin K activity associated with disease progression and therapeutic response in vivo. Cathepsin K expression is well known as a key biomarker and therapeutic target in a range of bone-related diseases, including cancer metastasis to bone, as well as in atherosclerosis. The new Cat-K FAST(TM) agent is expected to significantly expand research and enhance drug development in these areas by enabling real time imaging of Cat-K activity.

Cat-K FAST(TM) represents an additional protease-sensing agent developed and commercially launched based on VisEn's new FAST ("Fluorescent Activatable Sensor Technology") in vivo agent platform. FAST agents are based on high-performance, activatable smaller molecules that combine biomarker specificity with optimized biocompatibility and pharmacokinetics for precise measurement and monitoring of key disease biomarkers in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense(R), IntegriSense(TM), AngioSense(TM), OsteoSense(R) and MMPSense(TM). VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag(R) fluorescence labeling dyes for custom agent development, and its NanoSpark(R) labeling nanoparticles, all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging. All VisEn agents and labels, including the new Cat-K FAST(TM) agent, are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
2. VisEn Medical Raises $7 Million in Series B Financing
3. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
4. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
5. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
6. Novozymes Launches Enzyme to Reduce Acrylamide in Food
7. Enova Medical Launches Exos Corporation
8. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
9. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
10. ThirdBiotech Networking Group Launches
11. BioReliance Launches Next-Generation Genotoxicity Screening Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):